Results 171 to 180 of about 642,659 (199)

Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. [PDF]

Diabetes Care
Kang YM, Giugliano RP, Ran X, Deedwania P, De Ferrari GM, George JT, Gouni-Berthold I, Paiva da Silva Lima G, Handelsman Y, Lewis BS, Ohman EM, Wang H, López JAG, Monsalvo ML, Sabatine MS, Leiter LA.   +15 more
europepmc   +1 more source

A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8⁺ infiltration in glioma. [PDF]

Sci Rep
Singh K, Foster MW, Violette MJ, Corcoran AM, Hotchkiss KM, Railton CO, Blandford EE, Blethen KE, Thomas EL, McIntosh WC, Ashley DM, Desjardins A, Friedman HS, Johnson MO, Friedman A, Keir S, Buckley ED, Herndon JE, McLendon RE, Sampson JH, Calabrese E, López GY, Grant GA, Patel AP, Gregory SG, Li CY, Fecci PE, Khasraw M.   +27 more
europepmc   +1 more source

Oligogenic Familial Hypercholesterolemia Treated by Combination Therapy of Statin, Ezetimibe, PCSK9 Inhibitor, and Lomitapide. [PDF]

Intern Med
Kojima N, Tada H, Takamura M.
europepmc   +1 more source

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

JAMA
Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL.   +11 more
europepmc   +1 more source

Therapeutic Persistence in the Management of Familial Hypercholesterolemia: A Case of Acquired PCSK9 Inhibitor Nonresponse. [PDF]

JACC Case Rep
Lin KH, Stone NJ.
europepmc   +1 more source

Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis. [PDF]

Eur Heart J Cardiovasc Pharmacother
Goto S, Goto S.
europepmc   +1 more source

PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition. [PDF]

Int J Mol Sci
Quagliariello V, Berretta M, Bisceglia I, Iovine M, Barbato M, Arianna R, Canale ML, Paccone A, Inno A, Scherillo M, Oliva S, Cadeddu Dessalvi C, Mauriello A, Maurea C, Fonderico C, Maratea AC, Gabrielli D, Maurea N.   +17 more
europepmc   +1 more source

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy. [PDF]

Arterioscler Thromb Vasc Biol
Reijnders E, Bossuyt PM, Jukema JW, Ruhaak LR, Romijn FPHTM, Szarek M, Trompet S, Bhatt DL, Bittner VA, Diaz R, Fazio S, Stevanovic I, Goodman SG, Harrington RA, White HD, Steg PG, Schwartz GG, Cobbaert CM.   +17 more
europepmc   +1 more source

Effects of PCSK9 inhibitor evolocumab on preventing early neurological deterioration in acute ischemic stroke patients with or without large artery atherosclerosis: a subgroup analysis of a randomized trial. [PDF]

BMC Neurol
Liu J, Li Y, Tian W, Cao H, Li X, Cheng L, Ji X, Liu J.   +7 more
europepmc   +1 more source

Efficacy and safety of tafolecimab a new PCSK9 inhibitor in patients with hyperlipidemia: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Egypt Heart J
Ahmed AAS, Alkheder A, Ali MA, Abdelraouf MR, Ashour TA, Mohamed Salamah H, Mahmoud A, Hakim D.   +7 more
europepmc   +1 more source